Gastric Cancer Prevention in the Family Members by Helicobacter Pylori Eradication

• Status: Active, not recruiting
• Trial end date: 2023-12-01
• Target enrollment: 0
• Participant gender: All

Summary

This study evaluate whether treatment of Helicobacter pylori infection reduces the incidence of gastric cancer in subjects with family history of gastric cancer.

• Phase: Phase 3
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: National Cancer Center, Korea
• Treatments: Amoxicillin; Clarithromycin; Lansoprazole

Criteria

Inclusion Criteria:

• Sibling or offspring of patients with gastric adenocarcinoma confirmed by EGD and biopsy

• Informed consent should be signed

Exclusion Criteria:

• Gastric cancer history

• Other malignancy within the past 5 years

• Hereditary cancer family member (HNPCC, FAP)

• Peptic ulcer history

• Peptic ulcer, esophageal cancer, gastric cancer case found at EGD

• H. pylori eradication treatment history

• Previous serious side effect to antibiotics

• Serious concurrent infection or nonmalignant disease such as liver cirrhosis, renal failure, cardiovascular diseases

• Pregnant or nursing women

• Psychiatric disorder that would preclude compliance, alcoholics

• Refuse informed consent